# Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.

> **NCT04949386** · PHASE2 · UNKNOWN · sponsor: **SolAeroMed Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Post Acute COVID-19 Syndrome
- Long COVID
- COVID-19 Respiratory Infection

## Interventions

- **DRUG:** S-1226 (8%)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04949386
- **Lead sponsor:** SolAeroMed Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09
- **Primary completion:** 2021-12
- **Final completion:** 2022-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2021-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04949386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04949386, "Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04949386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*